- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Lupin Limited's Board has approved several key initiatives, including the reappointment of Ms. Vinita Gupta as CEO for five years starting May 28, 2025, and Mr. Ramesh Swaminathan as Executive Director and CFO for five years starting March 26, 2025, pending shareholder approval. The company plans to transfer its OTC Consumer Healthcare Business to a newly formed subsidiary, LupinLife Consumer Healthcare Limited, expected to generate ₹5,500 million to ₹6,500 million from the deal, with completion anticipated by June 30, 2025. Additionally, Lupin has introduced an Employee Stock Option Scheme 2025 for up to 10 million shares. These changes signal a strategic focus on enhancing operational efficiency and positioning in the growing OTC market, potentially boosting investor sentiment.